CABG术后在标准阿司匹林基础上加用替格瑞洛对大隐静脉桥血管通畅性的影响(POPular CABG)
POPular CABG 是一项随机、双盲、安慰剂对照、多中心试验,纳入499例CABG术后患者,1:1随机接受替格瑞洛或安慰剂联合标准阿司匹林(80或100 mg)。主要终点为1年时大隐静脉桥血管(SVG)闭塞,替格瑞洛组为10.5%(51/484),安慰剂组为9.1%(43/470),OR 1.29(95%CI 0.73-2.30),P=0.38。结论:在标准阿司匹林基础上加用替格瑞洛未减少CABG术后1年SVG闭塞。
要点
- CABG术后标准阿司匹林加替格瑞洛未降低1年SVG闭塞率。
- SVG闭塞率替格瑞洛组10.5% vs 安慰剂组9.1%,差异无统计学意义。
- SVG失败复合终点两组分别为14.2%与11.6%,OR 1.22(95%CI 0.72-2.05)。
核心结论
- 在标准阿司匹林基础上加用替格瑞洛未减少CABG术后1年大隐静脉桥血管闭塞。
研究设计与样本
- 研究者发起、随机、双盲、安慰剂对照、多中心试验,499例CABG术后有≥1条SVG的患者1:1随机接受替格瑞洛或安慰剂联合标准阿司匹林(80或100 mg)。
主要发现
- 替格瑞洛组SVG闭塞率为10.5%(51/484),安慰剂组为9.1%(43/470),OR 1.29(95%CI 0.73-2.30),P=0.38。
- SVG失败在替格瑞洛组发生35例(14.2%),安慰剂组29例(11.6%),OR 1.22(95%CI 0.72-2.05)。
- 主要终点影像学评估在替格瑞洛组220例、安慰剂组223例患者中进行。
临床怎么用
- 对于CABG术后患者,不支持常规在阿司匹林基础上加用替格瑞洛以预防1年SVG闭塞。
局限性
- 主要终点影像学评估仅在部分随机患者(替格瑞洛组220例、安慰剂组223例)中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 15% of saphenous vein grafts (SVGs) occlude during the first year after coronary artery bypass graft surgery (CABG) despite aspirin use. The POPular CABG trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting Surgery) investigated whether ticagrelor added to standard aspirin improves SVG patency at 1 year after CABG. METHODS: In this investigator-initiated, randomized, double-blind, placebo-controlled, multicenter trial, patients with ≥1 SVGs were randomly assigned (1:1) after CABG to ticagrelor or placebo added to standard aspirin (80 mg or 100 mg). The primary outcome was SVG occlusion at 1 year, assessed with coronary computed tomography angiography, in all patients that had primary outcome imaging available. A generalized estimating equation model was used to perform the primary analysis per SVG. The secondary outcome was 1-year SVG failure, which was a composite of SVG occlusion, SVG revascularization, myocardial infarction in myocardial territory supplied by a SVG, or sudden death. RESULTS: Among 499 randomly assigned patients, the mean age was 67.9±8.3 years, 87.1% were male, the indication for CABG was acute coronary syndrome in 31.3%, and 95.2% of procedures used cardiopulmonary bypass. Primary outcome imaging was available in 220 patients in the ticagrelor group and 223 patients in the placebo group. The SVG occlusion rate in the ticagrelor group was 10.5% (51 of 484 SVGs) versus 9.1% in the placebo group (43 of 470 SVGs), odds ratio, 1.29 [95% CI, 0.73-2.30]; P=0.38. SVG failure occurred in 35 (14.2%) patients in the ticagrelor group versus 29 (11.6%) patients in the placebo group (odds ratio, 1.22 [95% CI, 0.72-2.05]). CONCLUSIONS: In this randomized, placebo-controlled trial, the addition of ticagrelor to standard aspirin did not reduce SVG occlusion at 1 year after CABG. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02352402.
引用
- Willemsen LM, Janssen PWA, Peper J, et al. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2020. PMID: 32862716. doi:10.1161/CIRCULATIONAHA.120.050749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。